SARS-CoV-2 receptor ACE2 gene expression and RAAS inhibitors
Open Access
- 1 June 2020
- journal article
- letter
- Published by Elsevier BV in The Lancet Respiratory Medicine
- Vol. 8 (6), E50-E51
- https://doi.org/10.1016/S2213-2600(20)30224-1
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers What Is the Evidence?Jama-Journal Of The American Medical Association, 2020
- Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysisEuropean Respiratory Journal, 2020
- ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19European Respiratory Journal, 2020
- Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?The Lancet Respiratory Medicine, 2020
- The Management Transformation of HuaweiPublished by Cambridge University Press (CUP) ,2020
- Sex difference and smoking predisposition in patients with COVID-19The Lancet Respiratory Medicine, 2020
- Recombinant human ACE2: acing out angiotensin II in ARDS therapyCritical Care, 2017
- Correction: Lung eQTLs to Help Reveal the Molecular Underpinnings of AsthmaPLoS Genetics, 2012
- Lung eQTLs to Help Reveal the Molecular Underpinnings of AsthmaPLoS Genetics, 2012
- Angiotensin-converting enzyme 2 protects from severe acute lung failureNature, 2005